Patients with both acute and chronic autoimmune thrombocytopenic purpura (AITP) have in vitro lymphocyte defects in the form of platelet-stimulated proliferation and cytokine secretion. A blinded study was performed t o determine if these defects are related t o serum cytokine levels and/or platelet antigen expression. Compared with controls, 53% of children with chronic AITP, but only 9% of those with acute AITP, had increased serum interleukin-2 (IL-2). interferon-y, and/or 11-10; however, none of the patients had detectible serum levels of IL-4 or IL-6, cytokine patterns suggesting an early CD4+ Tho and T h l cell activation. In children with chronic AITP, the levels of serum IL-2 correlated with in vitro platelet-stimulated 11-2 production. Few (17%) patients with AITP showed platelet activation, as measured by CD62 expression, or abnormal expression levels of platelet membrane glycoprotein (GP) Ilbllla, but abnormal GPlb levels were observed in one-third of children with AITP. In contrast t o normal controls and patients with nonimmune thrombocytopenia, a significant number of children with acute (80%).
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UTOIMMUNE thrombocytopenic purpura (AITP) is a
A common immune-mediated bleeding disorder in which platelets are opsonized by autoantibodies and prematurely destroyed by the reticuloendothelial system. In children, both acute and chronic forms of the disease can be distinguished. Acute AITP in children is often preceded by viral or bacterial infections and generally resolves spontaneously within 6 weeks. Approximately 20% of children with acute AITP progress to the chronic form of AITP, defined as persistence of thrombocytopenia (platelet counts <150 X 109/L) for greater than 6 months.' In contrast, AITP in adults is generally chronic and often requires treatment with immunosuppressive therapy or splenectomy. Although both acute and chronic AITP are immune-mediated, different pathogenetic mechanisms may be responsible'; elucidation of such differences may permit identification of those children with acute AITP likely to develop the chronic form of the disorder.
Several studies have shown in vitro cellular immune defects in patients with both acute and chronic AITP,3-9 but little is known regarding serum cytokines in AITP and their relationship to the autoimmune pathogenesis. In addition, despite extensive study of platelet-associated immunoglobulins and complement, little is known of the platelet surface antigenic profile in AITP. Boshkov et all0 reported a patient with acute AITP who had 39% of his platelets expressing HLA-DR; this amount declined as platelet counts increased. We examined the hypothesis that platelet membrane abnormalities and abnormal serum cytokine levels may play a role in the immune pathogenesis in patients with AITP, particularly with respect to in vitro platelet-stimulated T-helper (Th) cell activation. It was found that enhanced platelet HLA-DR expression was common to all the forms of AITP, whereas increased levels of interleukin-2 (IL-2), interferon-y (IFNy ) , and/or IL-10 reflecting Tho and Thl cell activation were found primarily in the sera of patients with chronic AITP. chronic (71%). or chronic-complex (55%) AlTP had GPlb+ peripheral blood cells expressing HLA-DR. HLA-DR was variably coexpressed on distinct smaller and larger-sized GPlb' cell populations with CD41, CD45, CD14, CD80, and/or glycophorin molecules. GPlb' cells isolated from spleens of patients with chronic AlTP had high expression (49% ? 30%) of HLA-DR and splenic T cells had a high level of in vitro platelet-stimulated IL-2 secretion compared with controls. Platelet HLA-DR expression correlated inversely with platelet count, but not with therapy, serum cytokines, or in vitro lymphocyte antiplatelet reactivity. The results indicate that platelet HLA-DR expression is a common occurrence in patients with immune thrombocytopenia, whereas a large subpopulation of children with chronic AlTP can be identified by increased serum cytokine levels and in vitro platelet-stimulated IL-2 secretion by lymphocytes, suggesting that differences exist in the immune pathogenesis of acute and chronic AITP, particularly at the level of platelet reactive T cells. 0 1996 by The American Society of Hematology.
These results suggest that differences exist in the immune reactivity of Th cells in a significant number of children with chronic AITP compared with those with acute AITP and that such differences may be useful in distinguishing the two forms of the disorder. count <150 X 10'/L) persisting greater than 6 months, normal or increased marrow megakaryocytes, and no secondary immune or nonimmune abnormality that could account for the thrombocytopenic state. Chronic-complex AITP was defined as chronic AITP associated with immune neutropenia andor hemolytic anemia, often associated with other autoimmune disorders, eg, systemic lupus erythematosus, diabetes mellitus, dysgammaglobulinemia, or thyroid dysfunction. In addition, samples from 12 adult patients with nonimmune thrombocytopenia secondary to chemotherapy for acute leukemia were examined and samples from 16 normal healthy adult laboratory volunteers were tested as daily controls.
Preparation of peripheral blood mononuclear cells (PBMC), spleen cells, and platelets. For PBMC, heparinized blood was layered on a 1.077 g/mL Percoll cushion and centrifuged at 2,500g for 30 minutes and PBMC were aspirated from the top of the gradient and washed twice. Five children with chronic AITP underwent splenectomy during the study. Portions of the spleens were minced and crushed and fragments were allowed to settle in RPMI-1640. The spleen cell suspension in the supernatant was washed three times and platelets were analyzed directly from the suspension; splenic mononuclear cells were prepared by Percoll isolation as described above. For platelet antigen quantitation studies, peripheral blood was drawn into KSEDTA and immediately transferred into tubes containing 0.5 mL of a 0.5% paraformaldehyde (PFA) solution in saline to inhibit in vitro platelet activation during test manipulations." PFA-fixed platelets were isolated from platelet-rich plasma (PRP) as previously described." For three-color analysis of platelet populations, platelets were analyzed in whole blood.
Monoclonal antibodies used in platelet and lymphocyte phenofyping. Fluorescein isothiocyanate (F1TC)-labeled anti-CD41 and anti-CD42b were obtained from BioCan Scientific (Toronto, Ontario, Canada) and FITC-labeled antihuman IgG and C3 were obtained from Organon Teknika (Scarborough, Ontario, Canada) or Immunocorp Sciences Inc (Montreal, Quebec, Canada). Phycoerythrin (PE)-labeled antihuman IgM was obtained from Immunocorp Sciences. Monoclonal FITC-and PE-labeled isotype controls, PE-anti-CD62, PE-anti-CD80, PE-anti-HLA-DR, FITC-anti-CD13, PE-anti-CD4/ FITC-anti-CD3, PE-anti-CD14iFITC-anti-CD45, PE-anti-Leu8FlTC-anti-CD4, PE-anti-CDSFITC-anti-CDI 9, and PE-anti-HLA-DR/ FITC-anti-CD3 reagents were obtained from Becton Dickinson (San Jose, CA). Peridinin chlorophyll protein (PerCP)-labeled anti-HLA-DR was obtained from Becton Dickinson and used as a third-color fluorescent antibody.
For platelet antigen quantitation, PFA-fixed platelets isolated from PRP" were incubated with the indicated FITC-or PE-labeled antibodies for 30 minutes in the dark at 22"C, washed, and analyzed using a antibodies using the determined fluorescence/protein ratio. For threecolor analysis, platelets from whole blood or the spleen cell suspensions were incubated with the indicated labeled antibodies and acquired using forward scatter (FSC) and a fluorescent (FLl) threshold set on the lowest fluorescent channel of positive reactivity with FITC-anti-GPIb (CD42b) or -GPIIbIIIa (CD4la). Thirty thousand to 50,000 GPIb' or GPIIbIIIa+ events were acquired and analysis gates (R1 to R3) were set around the three distinct platelet populations. Analysis markers were set based on the appropriate isotype controls for all analyses.
Cytokine analysis. Sera from the patients and controls were tested for the presence of IL-2, IL-4, IL-6, IL-IO, and IFN-y with commercial solid-phase enzyme-linked immunosorbent assays (ELISAs; Cedarlane Laboratories and Immunocorp, Montreal, Quebec, Canada). Briefly, the sera were diluted 1:2 in phosphate-buffered saline (PBS) and coated onto 96-well ELISA plates preadsorbed with an anticytokine antibody for 2 hours at 22°C. An enzyme-linked anticytokine antibody was then added for an additional 2 hours. Substrate conversion was measured at 450 nm. Standard curves were generated with titrations of recombinant cytokines and were used to quantitate the serum cytokines in picograms per milliliter ranges. In our hands, the sensitivity of the cytokine assays were as follows: IL-2, >62.5 pg/mL; IL-IO, >31.25 pg/mL; IFN-y, >SO pg/mL; IL-4, >12.5 pg/mL; and IL-6, >6.25 pg/mL.
For determination of in vitro lymphocyte antiplatelet reactivity, 7-day antigen-presenting cell assays were performed.' Normal platelets (or autologous platelets when available) were titrated into cultures containing 2 X 10' PBMC or splenic mononuclear cells in 96-well round-bottom plates and incubated at 37°C for 6 days. Human allogeneic platelets have no in vitro stimulatory activity for resting T cells derived from normal individuals (data not shown). Supernatants were removed for IL-2 determinations and the cells were pulsed with 1 pCi of [3H]thymidine for an additional 24 hours and incorporated radioactivity was measured. IL-2 production was measured by a bioassay using the IL-2-dependent cell line, CTLL, as previously described.' The bioassay sensitivity was 0.1 U of IL-2 based on standard curves obtained with recombinant human IL-2 (GIBCO-BRL, Gaithersburg, MD).
To correct for daily variations in the assays, samples from at least 3 normal healthy adults were processed identically to the blinded test samples and included with each day's testing. Results were analyzed as absolute values and are presented as either absolute values or corrected for test variation by subtracting the mean daily control value (the delta [A] value). Normal ranges were established from the mean t 2 SD of results with normal children (N = 12). Nonparametric tests were used to evaluate differences in means between groups. Regression analysis was used to test the significance of correlations between parameters.
In vitro antiplatelet reactivity.
Analysis ofresulrs.

RESULTS
Serum cytokine levels.
A solid-phase ELISA was used to quantitate the levels of various cytokines in the sera of . and (Cl IFNy serum cytokine levels in the patient and control groups. Cytokine levels were determined by ELISA and assay sensitivities were determined to be as follows: IL-2, >62.5 pg/mL; IL-10, >31.25 pg/mL; and IFN-y, >50 pg/mL. Results are expressed as the cytokine concentration (in picograms per milliliter) of the sera samples. I L 4 and IL-6 results were negative in all the patients and controls IELISA sensitivities: IL4, >12.5 pglml; IL-6, >6.25 pg/mL; data not shown).
the patients and controls. Figure 1 shows the levels of (A) IL-2, (B) INF-y, and (C) IL-10 in both patients and controls.
Only 1 of 1 1 patients with acute AITP had significantly elevated levels of cytokines, ie, IL-2 (1,750 pg/mL), IL-10 (320 pg/mL), and IFN-y (500 pg/mL). However, in patients with chronic AITP, 9 of 17 patients had increased serum IL-2 (mean concentration, 360 pg/niL); 3 of the 9 also had elevated levels of IL-10 and 2 of these 3 patients had increased IFN-y. Three other patients with chronic AITP only had elevated serum levels of IL-10. Three of seven patients with chronic-complex AITP had increased serum IL-2; 2 of these 3 patients also had elevated levels of IFN-y and 1 of the 3 had detectible serum IL-10. The differences in the number of patients positive for serum IL-2 levels between acute and chronic AITP were significant (P < .001). Two children with chronic AITP were examined for serum cytokine levels on two occasions and were found to have consistent levels at both testing dates (eg, for IFN-y, 300 and 340 pg/mL for one child and 110 and 130 pg/mL for the second child). IL-4 and IL-6 serum levels were undetectable in the serum of all patients and controls in this study.
To assess whether PBMC from patients and controls produce IL-2 when stimulated with platelets in vitro, 7-day antigen-presenting cell (APC) assays were used. and IBI the correlation between in vivo and in vitro levels of 11-2. IL-2 levels in the supernatants were determined by a bioassay using CTLL cells, whereas those in serum were determined by ELISA. Results for in vitro-generated 11-2 are expressed as unlts per millilier and were calculated from standard curves using recombinant 11-2.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From 4240 SEMPLE ET AL from 12 of 19 of those with chronic AITP, and from 5 of 9 of those with chronic-complex AITP proliferated and secreted measurable IL-2 upon platelet stimulation. Of the in vitro responding cultures, patients with chronic AITP consistently had higher levels of IL-2 (mean, 3.6 U) in the culture supernatants, whereas lower amounts were seen in the APC cultures from those patients with acute AITP (mean, 0.7 U) or chronic-complex (mean, 0.6 U). In 6 of IO adult patients with chronic AITP (not otherwise included in this analysis), PBMC secreted IL-2 upon in vitro platelet stimulation (mean, 6 U). Splenic mononuclear cells from 4 of 5 patients with chronic AITP had the highest in vitro platelet-stimulated IL-2 production (mean, 12 U/mL). Figure 2B shows that in vitro antiplatelet T lymphocyte IL-2 secretion significantly correlated with the presence of increased serum IL-2 A number of patients in each group had abnormal platelet phenotype results, compared with the number tested. Increased platelet-associated (PA)-IgG was the most common Ig detected, being present in 73% and 65% of children with acute and chronic AITP, respectively, and in 82% of those with chronic-complex AITP. Increased PA-C3 was observed in approximately half of children with AITP and increased PA-IgM and PA-IgA were less frequently observed (40% and 5%, respectively). Figure 3A shows the individual A values by which the level varied from daily normal controls; the mean number of GPIIbIIIa molecules per platelet for the daily normal controls was 47.1 ? 2.8 X lo3 molecules/cell (N = 16). Few patients with AITP (6 of 40 children overall) showed abnormal levels of platelet surface GPIIbIIIa (CD4 1 a). The overall mean ? SD levels (X lo3 molecules/platelet) of GPIIbIIIa were 47.1 5 3.2 for acute AITP, 45.8 ? 6.9 for chronic AITP, and 49.4 ? 3.9 for chronic-complex AITP; these levels were not different from the levels observed in normal children (47.0 ? 3.2) or normal adults (48.4 t 1.6). Figure  3B shows the individual A values; the mean number of GPIb molecules per platelet for the daily normal controls was 19.9 t 1.4 X lo3. Fifteen of 43 children with AITP overall had abnormal levels of GPIb (CD42b) and this was most common in those with acute AITP (5 of 11 children). Mean t SD levels (X lo3) of GPIb were lower in normal children than in normal adults (18.2 ? 1.3 v 20.2 t 1.7, respectively; P < .005). The mean GPIb levels were 19.8 ? 4.9 for children with acute AITP, 20.9 2 3.1 for those with chronic AITP, and 20.6 t 2.7 for those with chronic-complex AITP; these were not different from normal adult values, but for chronic and chronic-complex AITP, the mean GPIb levels were increased from those of normal children (P < .02).
Platelet activation was assessed by CD62 (P-selectin; GMP140) expression. Immediate fixation in PFA was used to prevent in vitro platelet activation. Figure 3C shows the A values for platelets expressing CD62 for each individual; in normal children, the mean percentage of platelets expressing CD62 was 1.0% ? 1.5%. Only 17% of children with acute AITP and 13% of those with chronic AITP had an increase in platelets expressing CD62; an increase in platelets expressing CD62 was observed in 25% of children with chronic-complex AITP. Excluding 1 patient who had 35% ( I = .975, P < .001).
Platelet phenovpe.
of his platelets expressing CD62, the differences between patients with AITP and normal patients were not significant. When platelets were not fixed with PFA, 10% to 50% of the platelets from normal controls and from patients had increased expression of CD62. Figure 3D shows the A values for the platelets expressing HLA-DR in children with AITP; in the daily normal controls, the mean proportion of platelets expressing HLA-DR was 0.08% t 0.05%. Although in individual patients only small proportions of platelets expressed increased HLA-DR, most children with acute (80%), chronic (76%), or chronic-complex (55%) AITP exhibited a small but distinct increase in platelets expressing increased HLA-DR (defined as the mean channel fluorescence >2 SD above the mean for the daily normal controls). In normal children and in normal adults, 0.09% 2 0.06% and 0.13% -+ 0.12%, respectively, of platelets expressed HLA-DR ( P = S9). In contrast, there was a 10-fold increase (1.1% -t 0.9%) of platelets from patients with acute, chronic (0.9% -t 0.8%), and chronic-complex AITP (0.9% ? I. 1 %) expressing increased HLA-DR. Nonetheless, the majority of platelets remained HLA-DR-. Compared with normal children, the increases observed in platelets expressing HLA-DR were significant ( P < ,002 v acute AITP, P < .01 v chronic AITP, and P < .02 v chroniccomplex AITP). In 1 patient with acute AITP (not included in the calculations above), 24% of the platelets expressed HLA-DR. None of 12 patients with acute leukemia and nonimmune thrombocytopenia showed an increased number of platelets expressing HLA-DR, compared with normal controls (data not shown). Figure 4A through D shows a typical two-color flow cytometric analysis of PRP platelets derived from a healthy child (Fig 4A and C) and a child with chronic AITP (Fig 4B and  D) with 0.07% and 5.0%, respectively, of GPIb+ platelets expressing HLA-DR. Further characterization of HLA-DR' platelets was performed using three-color fluorescence. Figure 4E shows that GPIb' cells derived from the whole blood of a child with chronic AITP could be gated into three distinct populations based on size (forward light scatter; FSC) and a FITC-anti-GPIb threshold: GPIb' intact platelets (gate RI), GPIb+ macroparticles (gate R2), and GPIb' microparticles (gate R3). Microscopic examination of sorted populations showed that the macroparticle gate R2 was composed of single, nonadherent cells that on Giemsa staining were erythrocytes. Figure 4F shows results with PE-labeled antiglycophorin and PerCP-labeled HLA-DR antibodies of the ungated GPIb+ cells; greater than 98% of the glycophorinpositive events were contained in gate R2. HLA-DR expression was virtually absent on the whole blood GPIb+ cells from a healthy child control (0.06%; data not shown), but was increased (2.0%, P < ,001) on the GPIb' cells from the child with chronic AITP (Fig 4F) . Splenic GPIb' cells from the same child with chronic AITP had higher expression of HLA-DR (21%) compared with the whole blood platelets (2%). Spleens from 4 other children with chronic AITP had 49% 2 30% of their GPIb' cells expressing HLA-DR; each spleen showed higher HLA-DR expression than the corresponding peripheral blood platelets. Fig 4E. The increased peripheral blood GPIb' cell-associated HLA-DR expression in patients with AITP was associated with the larger-sized GPIb+glycophorin+ cells (gate R2; 6%), the smaller-sized GPIb' microparticles (gate R3; 4%), and the GPIb+ intact platelets (gate R1, 3%). The GPIb' cells in gates 2 and 3 also variably coexpressed CD45 (4% and 2%, respectively), CD14 (5% and 33%, respectively), and CD80 (4% and 22%, respectively) molecules. The glycophorinpositive events in gate 2 represented approximately 2% of total red blood cells in the blood sample. The observations on the peripheral blood platelets from patients with AITP were also seen, in greater degree, in platelets derived from the spleens of patients with chronic AITP, eg, a mean of 50% of gate 1 intact platelets expressed HLA-DR. Table 2 indicates that, in the other gated populations within spleenderived GPIb+ cells, there were, however, several significant differences in the coexpression of HLA-DR and CD45, CD14, CD80, and glycophorin compared with peripheral blood GPIb+ cells, eg, in splenic-derived cells in gate 2, 93% of the GPIb+/HLA-DR+ cells also expressed CD14, 80% coexpressed CD80, and 64% coexpressed glycophorin.
gated populations of GPIb+ cells shown in
Coexpression on single cells was confinned by examining sorted populations using fluorescent microscopy.
CorreZations between the results. Overall, there was an inverse correlation of platelet count with proportion of platelets expressing HLA-DR, as shown in Fig 5A (correlation   coefficient [r] = -3 3 7 , P < .01). In individual patients studied over time, as the platelet counts improved (with or without therapy), the number of platelets expressing HLA-DR was reduced (r = -3 3 1 , P < .01; data not shown).
On 9 of 10 occasions in which the platelet count increased, there was a decrease in platelet HLA-DR. On occasions in which the platelet count remained unchanged on subsequent testing, HLA-DR remained unchanged in 2 and increased in 1. One patient with chronic AITP (data not shown) was examined on 7 separate occasions (before and after IVIgG therapy, over the course of 7 months); the r value for relationship between HLA-DR expression and platelet counts in this patient was -.5730 (P = ,023). Platelet HLA-DR expression was not correlated to serum IL-2 levels (r = -.11, P = not significant [NS]; Fig 5B) , and it did not correlate with the other serum cytokine levels (data not shown).
In a number of cases, patients had received therapy within the month before testing. GPlb'GLY- DR->99  93  49  12  21  1  99  12  59  GPlb'GLY'DR-5  1   88  72  0  0  24  3  GPlb'G LY' DR  1  9  0  4  64  0  2  4  GPlb'GLY-DR'  2  41  0  3  35  0  2  34 Results are expressed as mean percentage of total cells within each gate (Rl-R3) shown in Fig. 4E . Fifty thousand events were acquired for analysis. The relative size of the cells within each gate are shown in Fig 4E ( there was no significant difference in GPlb+ cell size in control or patient groups).
Abbreviations: Co, GPlb* cells from whole blood of healthy control children (N = 10); Pat, GPlb' cells from whole blood of children with chronic AITP (N = 6); Pat Spl, GPlb' splenic cells from children with chronic AlTP (N = 4) ; NT, not tested.
For = 12; 2 in remission postsplenectomy); and IVIg, anti-D, steroids, and splenectomy in children with chronic-complex AITP (N = 5). There was no significant difference in number of patients on various therapies or receiving no treatment who had an increase in platelets expressing HLA-DR. None of 3 patients studied in remission had increased platelet HLA-DR expression. Analysis of variance failed to show correlation of any of the laboratory results (other than platelet count) with treatment.
DISCUSSION
Autoimmune pathogenesis may result, in part, from the immune-targeted tissue abnormally expressing self molecules such as HLA-DR, which in turn may activate autoreactive T lymphocytes and autoantibody ~ynthesis.'~-'~ Abnormal target tissue expression of HLA-DR has been described in autoimmune diseases, such as on the islet /? cells in type I diabetesI4 and on myelin in multiple scler~sis.'~ Transient expression of HLA-DR can be induced by inflammatory mechanisms and/or cytokines such as IFN-yI3 and may be responsible for increasing the intensity of an immune response or directing a tissue-specific immune response.I6 Because Boshkov et all0 in 1992 described a single patient with acute AITP who had increased platelet HLA-DR expression, which declined with response to therapy, we investigated platelet HLA-DR expression in patients with different forms of AITP. Because platelet dy~function'~.'~ and IgG-mediated platelet a c t i v a t i~n '~.~ have been described in AITP and these functional changes may be reflected by changes in platelet membrane antigen expression, we performed a blinded study in children with acute and chronic AITP to quantitatively assess changes in specific and nonspecific platelet surface molecules and to relate them to changes in serum cytokine levels and to in vitro platelet-stimulated activation by T lymphocytes.
Patients with acute AITP differed from those with the chronic form of the disorder in that, in the former, few patients had increased cytokines, whereas many (53%) of the latter had increased levels of serum IL-2, IFN-7, and/or IL-10. None of the patients tested had detectable serum levels of IL-4 or IL-6. 
IL-6.32
We found no detectable levels of IL-6 in these patients. The ability of IL-10 to suppress the production of inflammatory cytokines suggest that it may have a strong anti-inflammatory role in vivo33; although the role of IL-10 in chronic AITP is unclear, it may help in reducing antiplatelet reactivity and destruction. We are currently testing this hy- pothesis, but, at the present time, it remains unclear whether the alterations in cytokines play a primary role in the etiology of AITP or are rather a reflection of an ongoing inflammatory and/or immune response.
We7 and others' have previously reported that PBMC from patients with chronic AITP have enhanced platelet-stimulated IL-2 secretion in vitro. It was currently found that, in children with chronic AITP, serum cytokine levels correlated well with in vitro platelet-stimulated IL-2 production. In contrast, only 1 of 1 1 children with acute AITP had significant levels of serum IL-2, IL-10, and IFN-7, despite the fact that about one-third of these patients also have PBMC that mediated weak (0.7 U) in vitro platelet-stimulated IL-2 reactivity. These observations may relate to different immune pathogeneses in the various forms of AITP. Acute AITP may be due to a cross-reactive immune response directed against an infectious agent, eg, a virus,'4 whereas chronic AITP may be generated by a more platelet-specific autoimmune pathogenesis, possibly at the level of T cells. In acute AITP, the lymphocyte immune response, although slightly cross-reactive to normal platelets in vitro, may be due to a stimulus that does not generate the same serum cytokine profile as the autoimmune response directed at the platelets themselves in the chronic form of the disorder. The enhanced serum cytokine levels, the increase in activated T cells, and the strong in vitro antiplatelet T-cell response in patients with chronic AITP may be due to a continually plateletstimulated autoimmune response:.' We are currently studying these platelet-reactive T-cell responses at the clonal level.
A number of surface platelet-specific and nonspecific antigenic markers were quantitated in children with AITP and controls. Although some of the children with AITP in each group did exhibit abnormalities, in general, children with either the acute or chronic forms of AITP had platelets with normal expression of GPIIbIIIa and the CD62 activation molecule. These results support those of Chong et al, ' 5 who reported that, in contrast to patients with consumptive thrombocytopenia, plasma P-selectin levels were not increased in patients with AITP. The low expression of surface GPIIbIIIa observed in some patients (Fig 3A) may have been due to blocking by high-affinity autoantibodies to GPIIbIIIa, which are frequently present in chronic AITP.'6 An increase in GPIb expression, on the other hand, was present in one-third of the children with AITP and was more common in those with acute AITP; this may reflect a form of platelet activation, in which surface GPIb expression may be downregulated37 or ~pregulated.~' However, the observed increases, although statistically significant, were slight.
HLA-DR expression is normally primarily restricted to mature APC of the immune system, ie, monocytes/macrophages, dendritic cells, B cells, and activated T cells. Although megakaryocytes have been shown to express class I1 molecules on their surface in ~itt-0,'~ platelets normally express only HLA class I and not class I1 molecule^.^^^^^ However, the majority of the patients with AITP had a small but distinct increase in the proportion of platelets expressing HLA-DR. This was not seen in patients with nonimmune thrombocytopenia (data not shown) or in normal controls. Further three-color flow cytometric analysis indicated that the HLA-DR expression was coexpressed with GPIb and GPIIbIIIa on intact peripheral blood platelets and was also associated with CD14, CD45, and CD80 expression on platelet microparticles and macroparticles. These observations were particularly evident when splenic samples from patients with AITP were compared with the corresponding patients' peripheral blood platelets. Whereas the HLA-DR expression seen on GPIb-positive intact platelets may, as described above, have a role in the autoimmune pathogenesis of AITP, that seen on microparticles may reflect destructive mechanisms, ie, platelet fragments may combine with leukocyte (monocyte) fragments, yielding microparticles expressing both platelet and leukocyte antigens. The amplified findings in the spleen samples may reflect the locus of destruction, with the peripheral blood samples reflecting only those cells not sequestered or destroyed in the spleen. However, the data presented on the splenic platelet HLA-DR expression need to be interpreted with caution because there were no control spleen samples available for analysis. Nonetheless, the observations in the spleen may have a potential relationship to platelet destruction in AITP and should be further studied. The inverse correlation of platelets expressing HLA-DR and the platelet count supports this hypothesis.
Although platelet HLA-DR expression was of low levels, 1 patient with acute AITP had a dramatic increase in platelet HLA-DR (24%) that was similar to that found by Boshkov et all0 (39%) in acute AITP. However, because only 1 of 11 patients had a significant increase in platelet HLA-DR expression, it does not appear to be a common finding of acute AITP. The expression of HLA-DR on platelets was not correlated to serum cytokine levels. This may be due to either the number of patients being too low for statistical significance or it may indicate that other mechanisms are responsible for the expression. These mechanisms may include the passive adsorption of HLA-DR from membrane fragments of activated macrophages or possibly release of endogenous HLA-DR by the platelets themselves. However, we were consistently unable to show increased HLA-DR expression on normal platelets after thrombin or ADP stimulation and activation of the platelets (data not shown), suggesting that this pathway of endogenous release to the surface is not the likely mechanism. Furthermore, HLA-DR expression was not seen on young (as assessed by thiazole orange-detected RNA content) platelets from patients recovering from chemotherapy, suggesting that it is not the result of studying megakaryocytic platelets. On the other hand, the cells coexpressing GPIb and glycophorin in patients with AITP may relate to the observations by K a r~a t k i n~~ of increased red blood cell destruction in AITP.
Approximately 20% of children with acute AITP will progress to the chronic form of the disease.' It would be beneficial if markers of this transition were available. Although Ware and Howard' found no major phenotypic differences in T cells between children with acute and chronic AITP, functional analyses showed that the majority of platelet-reactive T-cell clones were derived from the children with chronic AITP. None of the platelet phenotypic markers investigated in the current report clearly distinguished the different clinical forms of AITP; however, we are observing these children to determine if these results may have a predictive value for determining progression to chronic AITP. Increased serum cytokines, together with in vitro plateletstimulated IL-2 production, may be important tests in examining differences in the pathophysiology of the acute and chronic forms of AITP and may help predict which children with acute AITP will develop the chronic form of the disease.
